Trend of antimicrobial susceptibility of P.aeruginosa isolates from UTI and RTI of Japanese hospital participating in the levofloxacine surveillance group during 19942010
Abstract number: R2332
Akira O., Yoshikazu I., Kazuhiro T., Keizo Y.
Objectives:Pseudomonas aeruginosa has become ploblematic because of an outbreak of multidrug-resistant clone producing metallo-b-lactamases (MBLs). We have already been taken nationwide surveillance for FQ and other antimicrobials resistance against many bacterial clinical isolates since 1994 in Japan. In this study, we report surveillance data for P. aeruginosa isolates from patients with urinary tract infection (UTI) and with respiratory tract infection (RTI) collected between 19942010.
Methods: A total of 7,019 clinical isolates (3,232 isolates from UTI and 3,787 isolates from RTI) were collected from 92 centers participating in the Levofloxacin Surveillance group during 19942010 in Japan. Antimicrobial susceptibility testing by broth microdilution methods was based on Clinical and Laboratory Standards Institute (CLSI) guidelines that were updated annually as revised documents were published.
Results and Discussions:
1UTI; The 'Susceptible' rate for levofloxacin has particularly increased over time (from 41.8% in 1994 to 74.2% in 2010). Although the cause of this increase is obscure, recent request for strict observance of the dosing period is probably implicated because drug use reviews do not show any decrease of the amount of levofloxacin used nationwide in the field of urology. Amikacin and ceftazidime also showed a gradual increase of the 'Susceptible' rate. The susceptibility for imipenem remained unchanged. The rate of 4 drugs resistant isolate to levofloxacin, ceftazidime, amikacin and imipenem was about 1% until 1998, however increased to 4.6% abruptly in 2000 and then shifted at the level of approximately 4%.
2RTI; The 'Susceptible' rate to levofloxacin, amikacin, ceftazidime and imipenem has been maintained constantly at a level of approximately 80%, 97%, 88% and 70%, respectively. The rate of 4 drugs resistant isolate to levofloxacin, ceftazidime, amikacin and imipenem was in a moderate increase in comparison with that in UTI.
3Metallo-b-lactamase; The rate of metallo-b-lactamase producing isolates from UTI and RTI was 8.0% in 2002, 7.2% in 2004 and 5.6% in 2007 (UTI), and 1.5% in 2002 1.0% in 2004 and 2.2% in 2007 (RTI), respectively.
|Session name:||Abstracts of 21st ECCMID / 27th ICC|
|Location:||Milan, Italy, 7 - 10 May 2011|
|Back to top|